Janssen
The Competition Bureau announced Wednesday, February 20, that it closed an investigation into allegations of abuse of dominance by Janssen, a Canadian pharmaceutical company owned by Johnson & Johnson. The Bureau’s investigation considered whether Janssen was engaging in conduct that shielded its biologic drug, Remicade, from competition from biosimilar drugs, like Inflectra and Renflexis. This […]
Arrowhead Pharmaceuticals has signed a license and collaboration agreement with Janssen Pharmaceuticals for the development and commercialization of hepatitis B virus (HBV) treatment, ARO-HBV. ARO-HBV is the third generation subcutaneously administered RNA interference (RNAi) therapy of Arrowhead being developed as a potential curative therapy for patients with chronic HBV infection. The companies have also signed […]
Featured News
Compass Faces New Federal Antitrust Fight Over Private Home Listings
Oct 22, 2026 by
CPI
Deutsche Boerse’s $6 Billion Allfunds Deal Faces EU Decision by Nov. 27
Oct 22, 2026 by
CPI
German Court Orders MAN, Daimler Truck to Compensate Customers in Price-Fixing Case
Oct 22, 2026 by
CPI
FTC Brings Antitrust Enforcement to Dallas
Oct 22, 2026 by
CPI
Publishers Urge EU, UK Regulators to Block Meta’s New Terms
Oct 22, 2026 by
CPI
Antitrust Mix
Antitrust Chronicle® – EU Merger Guidelines
Oct 19, 2026 by
CPI
In Praise of Theories of Benefits
Oct 19, 2026 by
Cyril Hariton & Pierre Regibeau
Closing the Efficiencies Gap
Oct 19, 2026 by
Kasia Czapracka & Marika Harjula
Analysis of Dynamic Trade-Offs Under the New Guidelines: Would Cases Like Amazon/Irobot Turn Out Differently?
Oct 19, 2026 by
Oliver Latham, Sam Marden, Saul Mendelsohn & Serge Moresi
Exploitative Portfolio Effects In EU Merger Control: From Mars/Kellanova to the Draft Merger Guidelines
Oct 19, 2026 by
Niels Baeten, Danette Chan & Elizabeth Malik